Shares of Prothena Corporation PLC (NASDAQ:PRTA) have received a consensus rating of “Buy” from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $77.80.
Several brokerages have recently issued reports on PRTA. Zacks Investment Research downgraded shares of Prothena Corporation PLC from a “buy” rating to a “hold” rating in a research report on Monday, May 15th. ValuEngine downgraded shares of Prothena Corporation PLC from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 27th. Oppenheimer Holdings, Inc. set a $70.00 target price on shares of Prothena Corporation PLC and gave the company a “buy” rating in a research report on Thursday, May 11th. Wedbush reiterated an “outperform” rating and issued a $77.00 price target on shares of Prothena Corporation PLC in a research note on Monday, April 3rd. Finally, Piper Jaffray Companies initiated coverage on shares of Prothena Corporation PLC in a research note on Wednesday, April 12th. They issued an “overweight” rating and a $69.00 price target for the company.
Prothena Corporation PLC (NASDAQ:PRTA) traded up 3.18% during midday trading on Monday, reaching $54.19. The company had a trading volume of 247,065 shares. Prothena Corporation PLC has a 52-week low of $33.53 and a 52-week high of $68.18. The company’s market capitalization is $2.06 billion. The company’s 50 day moving average is $53.21 and its 200-day moving average is $52.73.
Prothena Corporation PLC (NASDAQ:PRTA) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.99) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.32) by $0.33. Prothena Corporation PLC had a negative net margin of 16,012.49% and a negative return on equity of 39.67%. The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.26 million. During the same quarter in the prior year, the firm earned ($0.81) earnings per share. The business’s quarterly revenue was down 3.7% on a year-over-year basis. Equities analysts expect that Prothena Corporation PLC will post ($4.76) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/prothena-co-plc-prta-receives-76-70-consensus-price-target-from-analysts-updated-updated-updated/804385.html.
In related news, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $55.86, for a total transaction of $195,510.00. Following the transaction, the director now owns 6,345 shares in the company, valued at approximately $354,431.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction on Monday, April 17th. The shares were sold at an average price of $52.25, for a total transaction of $261,250.00. Following the transaction, the insider now owns 3,000 shares in the company, valued at approximately $156,750. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in PRTA. Ameritas Investment Partners Inc. acquired a new stake in Prothena Corporation PLC during the first quarter valued at approximately $167,000. Stifel Financial Corp purchased a new stake in shares of Prothena Corporation PLC during the first quarter worth about $224,000. Karp Capital Management Corp purchased a new stake in shares of Prothena Corporation PLC during the first quarter worth about $243,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Prothena Corporation PLC during the first quarter worth about $273,000. Finally, Focused Wealth Management Inc increased its stake in shares of Prothena Corporation PLC by 7.8% in the fourth quarter. Focused Wealth Management Inc now owns 6,250 shares of the biotechnology company’s stock worth $307,000 after buying an additional 450 shares during the last quarter.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with our FREE daily email newsletter.